Dale G. Renlund

Q: What Schools Are Affiliated With Dale G. Renlund

Dale G. Renlund is affiliated with the following schools: Johns Hopkins University, University of Utah

Why Is Dale G. Renlund Influential?

According to Wikipedia, Dale Gunnar Renlund is an American religious leader and former cardiologist who serves in the Quorum of the Twelve Apostles of the Church of Jesus Christ of Latter-day Saints . He has been a general authority of the church since 2009. Currently, he is the twelfth most senior apostle in the church.

(See a Problem?)

Dale G. Renlund's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Which white blood cell subtypes predict increased cardiovascular risk? (2005) (852)
A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. (1998) (591)
Ischemic Heart Disease Events Triggered by Short-Term Exposure to Fine Particulate Air Pollution (2006) (560)
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. (1995) (394)
Risk factors predictive of right ventricular failure after left ventricular assist device implantation. (2010) (362)
A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. (1992) (351)
Consensus statement: Palliative and supportive care in advanced heart failure. (2004) (327)
Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. (1989) (326)
A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. (1999) (299)
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. (1999) (287)
Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. (1990) (271)
Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. (1991) (243)
Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. (2005) (227)
Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. (1991) (225)
Left Ventricular Assist Device as Destination for Patients Undergoing Intravenous Inotropic Therapy: A Subset Analysis From REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure) (2004) (212)
Relation of heart failure hospitalization to exposure to fine particulate air pollution. (2008) (152)
Improvements in 1-Year Cardiovascular Clinical Outcomes Associated with a Hospital-Based Discharge Medication Program (2004) (147)
Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. (2010) (134)
Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. (2009) (129)
Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. (2000) (123)
Effects of acute beta-adrenergic receptor blockade on age-associated changes in cardiovascular performance during dynamic exercise. (1994) (123)
Task force 5: Complications (1993) (122)
THE USE OF MYCOPHENOLATE MOFETIL (RS‐61443) IN HUMAN HEART TRANSPLANT RECIPIENTS (1993) (120)
Lisinopril Lowers Cardiac Adrenergic Drive and Increases, 8‐Recept or Density in the Failing Human Heart (1993) (118)
Perfusate sodium during ischemia modifies post-ischemic functional and metabolic recovery in the rabbit heart. (1984) (118)
Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. (1987) (114)
beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. (1993) (114)
Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. (2007) (110)
New UNOS rules: historical background and implications for transplantation management. United Network for Organ Sharing. (1999) (100)
Improving outcomes with long-term "destination" therapy using left ventricular assist devices. (2008) (100)
Exceptional mortality prediction by risk scores from common laboratory tests. (2009) (100)
Use of the Frank-Starling mechanism during submaximal versus maximal upright exercise. (1986) (98)
Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. (1988) (96)
OUTCOME OF CARDIAC TRANSPLANT RECIPIENTS WITH A POSITIVE DONOR‐SPECIFIC CROSSMATCH—PRELIMINARY RESULTS WITH PLASMAPHERESIS (1992) (95)
Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. (1994) (94)
Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. (2007) (94)
Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. (1995) (93)
The cost of medical management in advanced heart failure during the final two years of life. (2008) (88)
Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. (2006) (87)
Usefulness of routine periodic fasting to lower risk of coronary artery disease in patients undergoing coronary angiography. (2008) (85)
Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. (2009) (81)
Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. (1991) (81)
Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. (1990) (80)
Echocardiographic evaluation of potential cardiac transplant donors. (1988) (78)
PREVENTION OF Pneumocystis carinii PNEUMONIA IN CARDIAC TRANSPLANT RECIPIENTS BY TRIMETHOPRIM SULFAMETHOXAZOLE (1993) (77)
Percutaneous coronary interventions with stents in cardiac transplant recipients. (2005) (75)
Cardiac transplantation in situs inversus. (1990) (74)
Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations. (1993) (73)
Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. (1995) (72)
Generating Genetic Risk Scores from Intermediate Phenotypes for Use in Association Studies of Clinically Significant Endpoints (2005) (71)
Genome-Wide Significance and Replication of the Chromosome 12p11.22 Locus Near the PTHLH Gene for Peripartum Cardiomyopathy (2011) (70)
Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3,170 biopsies. (2005) (69)
The Intermountain Risk Score (including the red cell distribution width) predicts heart failure and other morbidity endpoints (2010) (68)
Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24 months after transplantation. (1999) (66)
Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. (2009) (66)
Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. (2006) (65)
Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. (2006) (64)
Hypercholesterolemia after heart transplantation: amelioration by corticosteroid-free maintenance immunosuppression. (1989) (63)
Successful treatment of a cardiac angiosarcoma with combined modality therapy. (1994) (63)
Immunosuppressive therapy, management, and outcome of heart transplant recipients during pregnancy. (1993) (62)
Vascular rejection of human cardiac allografts and the role of humoral immunity in chronic allograft rejection. (1991) (61)
Predictors of survival after repeat heart transplantation (1992) (60)
24th Bethesda conference: Cardiac transplantation. Task Force 5: Complications. (1993) (59)
Major Abdominal Complications Following Cardiac Transplantation (1989) (59)
Pregnancy in Heart Transplant Recipients: Management and Outcome (1993) (59)
Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. (1987) (59)
A PROSPECTIVE COMPARISON OF MURINE MONOCLONAL CD‐3 (OKT3) ANTIBODY‐BASED AND EQUINE ANTITHYMOCYTE GLOBULIN‐BASED REJECTION PROPHYLAXIS IN CARDIAC TRANSPLANTATION (1989) (59)
Outcome of noncardiac surgery in patients with ventricular assist devices. (2009) (57)
Method for isolation of human ventricular myocytes from single endocardial and epicardial biopsies. (1995) (54)
Left ventricular assist device malfunction: a systematic approach to diagnosis. (2004) (54)
A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation. (2009) (53)
The Paradox of Obesity in Patients with Heart Failure (2005) (52)
Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. (1996) (52)
Age-associated decline in cardiac allograft rejection. (1987) (51)
Exercise capacity after heart transplantation: influence of donor and recipient characteristics. (1996) (51)
Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions. (2007) (51)
Use of OKT3 monoclonal antibody in heart transplantation: Review of the initial experience (1988) (49)
Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. (1999) (48)
Incremental survival benefit with adherence to standardized heart failure core measures: a performance evaluation study of 2958 patients. (2008) (48)
Long-term outcomes of cardiac transplantation for peri-partum cardiomyopathy: a multiinstitutional analysis. (2007) (47)
Early screening for antibody-mediated rejection in heart transplant recipients. (2007) (46)
Effect of mechanical circulatory support on outcomes after heart transplantation. (2006) (45)
Long-term results of cardiac transplantation in patients older than sixty years (1996) (45)
Detection of allograft endothelial cells of recipient origin following ABO-compatible, nonidentical cardiac transplantation. (1991) (43)
Increased cardiac allograft rejection in female heart transplant recipients. (1988) (42)
Effect of reversible pulmonary hypertension on outcomes after heart transplantation. (2007) (41)
Clinical manifestations of vascular rejection in cardiac transplantation. (1991) (41)
Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. (1996) (40)
Cardiac retransplantation: a viable option? The Registry of the International Society for Heart and Lung Transplantation. (1992) (40)
Influence of corticosteroid-free maintenance immunosuppression on allograft coronary artery disease after cardiac transplantation. (1990) (39)
Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantation. (1999) (39)
Left ventricular mass increases during cardiac allograft vascular rejection. (1995) (38)
Effects of the 2006 U.S. thoracic organ allocation change: analysis of local impact on organ procurement and heart transplantation. (2010) (37)
Less affluent area of residence and lesser-insured status predict an increased risk of death or myocardial infarction after angiographic diagnosis of coronary disease. (2004) (36)
Cardiovascular response to exercise in younger and older men. (1987) (34)
Evidence that human cardiac allograft acceptance is associated with a decrease in donor-reactive helper T lymphocytes. (1995) (34)
Use of Orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection. (1987) (34)
Corticosteroid-free maintenance immunosuppression after heart transplantation: feasibility and beneficial effects. (1992) (34)
Mediastinitis in heart transplantation. (1992) (34)
Guillain-Barré syndrome following coronary artery bypass surgery. (1987) (34)
Calcium-dependent enhancement of myocardial diastolic tone and energy utilization dissociates systolic work and oxygen consumption during low sodium perfusion. (1985) (33)
The repetitive histologic pattern of vascular cardiac allograft rejection. Increased incidence associated with longer exposure to prophylactic murine monoclonal anti-CD3 antibody (OKT3). (1996) (33)
Up-regulation of beta 2-adrenergic receptors in previously transplanted, denervated nonfailing human hearts. (1993) (31)
Methotrexate as an adjunct in the treatment of persistent mild cardiac allograft rejection. (1990) (31)
Differences in β‐Adrenergic Neuroeffector Mechanisms in Ischemic Versus Idiopathic Dilated Cardiomyopathy (1991) (31)
Multivariate predictors of heart transplantation outcomes in the era of chronic mechanical circulatory support. (2007) (30)
Tricuspid valve dysfunction in the transplanted heart. (1995) (30)
Effect of ABO-incompatible listing on infant heart transplant waitlist outcomes: analysis of the United Network for Organ Sharing (UNOS) database. (2009) (29)
Interaction between left ventricular end-diastolic and end-systolic volumes in normal humans. (1990) (29)
Increased frequency of alloantigen-reactive helper T lymphocytes is associated with human cardiac allograft rejection. (1993) (28)
The impact of bridge-to-transplant ventricular assist device support on survival after cardiac transplantation. (2010) (28)
The high risk heart donor: potential pitfalls. (1995) (28)
Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure. (2005) (26)
Do statins increase the risk of idiopathic polyneuropathy? (2005) (26)
OKT3 monoclonal antibody in heart transplantation. (1988) (26)
Homocysteine Levels Are Associated with Increased Risk of Congestive Heart Failure in Patients with and without Coronary Artery Disease (2006) (26)
Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. (2006) (25)
An avoidable pitfall in donor selection for heart transplantation. Utah Heart Transplant Program. (1989) (24)
A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction. (2004) (23)
Acute vascular rejection involving the major coronary arteries of a cardiac allograft. (1988) (22)
Treatment of cytomegalovirus pneumonia in heart transplant recipients with 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG). (1988) (22)
Predictors of survival after repeat heart transplantation. The Registry of the International Society for Heart and Lung Transplantation, and Contributing Investigators. (1992) (22)
TREATMENT OF MYOCARDITIS WITH OKT3 MONOCLONAL ANTIBODY (1988) (21)
Effect of preoperative hemodynamic support on survival after cardiac transplantation. (1988) (21)
Laser backscatter studies of intracellular Ca2+ oscillations in isolated hearts. (1989) (20)
Early postoperative use of unfractionated heparin or enoxaparin is associated with increased surgical re-exploration for bleeding. (2005) (19)
Adjuvant intrapleural amphotericin B therapy for pulmonary mucormycosis in a cardiac allograft recipient. (1997) (19)
Immunosuppression following cardiac transplantation. (1990) (19)
Antilymphocyte-antibody prophylaxis: review of the adult experience in heart transplantation. (1997) (18)
Low-dose enoximone in subjects awaiting cardiac transplantation. Clinical results and effects on beta-adrenergic receptors. (1991) (18)
Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients. (2006) (18)
Comparison of the beta blocker bucindolol in younger versus older patients with heart failure. (2002) (18)
Enoximone as a bridge to heart transplantation: the Utah experience. (1991) (18)
Becker muscular dystrophy-related cardiomyopathy: a favorable response to medical therapy. (2002) (17)
β‐Blockade With Bucindolol in Heart Failure Caused by Ischemic Versus Idiopathic Dilated Cardiomyopathy (1991) (17)
Efficacy of OKT3 retreatment for refractory cardiac allograft rejection. (1989) (17)
Survival following cardiac transplantation--what are acceptable standards? (1987) (17)
Cardiac transplantation in survivors of lymphoma: a multi-institutional survey. (2000) (16)
Methotrexate therapy in pediatric heart transplantation as treatment of recurrent mild to moderate acute cellular rejection. (1994) (16)
Medical aspects of cardiac transplantation. (1988) (16)
When the failing, end-stage heart is not end-stage. (2006) (16)
Tricuspid valve replacement after cardiac transplantation. (2005) (16)
Perioperative mechanical circulatory support for transplantation. (1992) (16)
Long-term results of cardiac transplantation in patients older than sixty years. UTAH Cardiac Transplant Program. (1996) (15)
Medicare-designated centers for cardiac transplantation. (1987) (14)
Time-dependent changes in B-type natriuretic peptide after heart transplantation: correlation with allograft rejection and function. (2009) (14)
Incidence of adenomatous colorectal polyps in cardiac transplant recipients. (1997) (14)
Cardiac allograft function with corticosteroid-free maintenance immunosuppression. (1990) (13)
A PROSPECTIVE, RANDOMIZED COMPARISON OF CYCLOPHOSPHAMIDE AND AZATHIOPRINE FOR EARLY REJECTION PROPHYLAXIS AFTER CARDIAC TRANPLANTATION DECREASED SENSITIZATION TO OKT3 (1994) (13)
OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation. (1989) (13)
Superior predictive ability for death of a basic metabolic profile risk score. (2009) (13)
Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss. (1991) (12)
C-Reactive Protein Predicts Death in Patients with Non-Ischemic Cardiomyopathy (2005) (12)
Impact of dose reductions on efficacy outcome in heart transplant patients receiving enteric‐coated mycophenolate sodium or mycophenolate mofetil at 12 months post‐transplantation (2008) (11)
Murine monoclonal CD3 antibody (OKT3)-based early rejection prophylaxis in pediatric heart transplantation. (1993) (11)
Building a bridge to heart transplantation. (2004) (11)
Prolonged decrease in cardiac volumes after maximal upright bicycle exercise. (1987) (11)
Major abdominal complications following cardiac transplantation. Utah Transplantation Affiliated Hospitals Cardiac Transplant Program. (1989) (11)
Paternity by cardiac transplant recipients. (1994) (10)
Antimurine antibody to OKT3 in cardiac transplantation: implications for prophylaxis and retreatment of rejection. (1991) (10)
Task force 6: Future developments (1993) (10)
Three-Year Allograft Vasculopathy Results of the Multicenter Heart Transplant Mycophenolate Mofetil Randomized Trial (1999) (10)
Early rejection prophylaxis in heart transplantation: is cytolytic therapy necessary? (1989) (10)
Cyclophosphamide in cardiac transplant recipients with frequent rejection: a six-year retrospective review. (1996) (9)
Cardiac allograft vascular (microvascular) rejection (2002) (9)
The quantitative flow cytometric plasma OKT3 assay. Its potential application in cardiac transplantation. (1989) (9)
Diagnosis and treatment of cardiac allograft rejection. (1990) (8)
Increased expression of β2-adrenergic receptors in surgically denervated, previously transplanted human ventricular myocardium (1990) (8)
An institutional discharge medication program reduces future cardiovascular readmissions and mortality: an analysis of 43,841 patients with coronary artery disease (2002) (7)
The first pediatric Japanese case to undergo heart transplantation in the Utah Cardiac Transplant Program in the United States. (1993) (7)
Post-transplant lymphoproliferative disease in cardiac transplant patients receiving OKT3 therapy (1992) (7)
Variations in the diagnosis, treatment, and prevention of cardiac allograft rejection: the need for standardization? (1990) (7)
OKT3 for induction of immunosuppression and treatment of rejection in cardiac allograft recipients (1993) (6)
810-5 Use of either metformin or thiazolidinedione is associated with improved survival among patients with type 2 diabetes from a registry of 16,203 diabetic patients (2004) (6)
Use of enoximone in patients awaiting cardiac transplant. (1988) (6)
Enoximone in severe heart failure: clinical results and effects on β-adrenergic receptors (1990) (5)
Bridging the resource gap in heart failure expertise and management: the underacknowledged role of nurse specialists. (2005) (5)
Is atrial fibrillation an inflammatory disease reflected by elevated C-reactive protein? (2003) (5)
Cardiac transplantation in a patient with a single ventricle and transposition of the great vessels. (1991) (5)
A RANDOMIZED TRIAL OF THE IMMUNOSUPPRESSIVE EFFICACY OF VINCRISTINE IN CARDIAC TRANSPLANTATION (1990) (4)
Cardiac allograft cellular rejection during OKT3 prophylaxis in the absence of sensitization. (1991) (4)
147: Outcomes of Heart Transplantation for Peripartum Cardiomyopathy: Analysis of the United Network for Organ Sharing (UNOS) Database (2009) (4)
The intricacies of heart failure. (2007) (4)
CARDIAC TRANSPLANTATION IN SURVIVORS OF LYMPHOMA (2000) (4)
Generic drug substitution in transplantation: Examples from the epic of cyclosporine development (2000) (4)
Murine monoclonal CD3 antibody (OKT3) in cardiac transplantation: three-year experience (1989) (4)
Angina: current approaches to diagnosis, drug therapy, and surgical referral. (1986) (4)
Immunosuppressive efficacy of vincristine in heart transplantation: a preliminary report. (1987) (4)
Similar transplantation outcomes in patients bridged with cardiac assist devices for acute cardiogenic shock versus chronic heart failure (2007) (4)
Heart failure epidemic boiling to the surface. (2006) (3)
Exercise and the aging heart. (1987) (3)
The Effect of Postural Changes on Intracardiac Filling Pressures (2008) (3)
Six month data of a 12-month, single-blind, randomized, parallel group, multicenter study to investigate the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic®) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients (2004) (3)
Strategies of immunosuppression in cardiac transplantation. (1990) (3)
Differences in /3-Adrenergic Neuroeffector Mechanisms in Ischemic Versus Idiopathic Dilated Cardiomyopathy (2005) (3)
Sodium modulation of resting force, contractile properties, and metabolism with particular emphasis on its role in the development of calcium overload states. (1986) (3)
Inadequate prediction of death by the framingham risk model for patients with existing, angiographically- defined coronary artery disease (2002) (2)
336: Participation in end of life decisions with destination left ventricular assist device therapy (2007) (2)
Improved long-term survival associated with stent deployment during percutaneous coronary interventions: results from a registry of 3399 patients. (2005) (2)
Long-term morbidity of cyclosporine with corticosteroid-free maintenance immunosuppression in cardiac transplantation. (1990) (2)
Malignancy and death from malignancy after heart transplantation, a multicenter time related risk analysis (2002) (2)
Methotrexate for rejection prophylaxis after heart transplantation. (1995) (2)
Cardiovascular deaths in heart transplant recipients: Does the rejection pattern matter? (2005) (2)
Genome-wide Significance and Replication of the Chromosome 12 p 11 . 22 Locus Near the PTHLH Gene for Peripartum Cardiomyopathy Running title : Horne et al . ; Chromosome 12 p 11 . 22 for Peripartum Cardiomyopathy (2011) (2)
Effect of mechanical circulatory support on outcomes after heart transplantation in the modern era (2004) (2)
Fibrinoid necrosis of a temporal artery complicating the treatment of refractory cardiac allograft rejection with murine monoclonal CD3 antibody (OKT3). (1990) (2)
Fasting and other health influences. (2009) (2)
Early failure of a tricuspid valve replacement with a mitral valve homograft in a heart transplant recipient. (2004) (2)
Aging and cardiac function. (1986) (2)
Cytomegalovirus: Strength of antibody response and its relationship to risk of mortality among patients with angiographic coronary disease (2003) (2)
PATIENT SELECTION SCALE FOR DESTINATION THERAPY LEFT VENTRICULAR ASSIST DEVICE PLACEMENT (2006) (1)
198: Fibrin deposition in cardiac allograft rejection: An incidental finding or a prognostic marker? (2007) (1)
Everolimus dose recommendations in de novo heart transplantation - TDM simulations (2003) (1)
24th Bethesda conference: Cardiac transplantation. Task Force 6: Future developments. (1993) (1)
334: Identification of Genome-Wide Single Nucleotide Polymorphisms in Peripartum Cardiomyopathy (2009) (1)
Successful implementation of heart failure self management tools improves survival (2005) (1)
Abstract 3642: Fasting, a Novel Indicator of Religiosity, may Reduce the Risk of Coronary Artery Disease (2007) (1)
Abstract 2939: Heart Failure Exacerbation and Exposure to Fine Particulate Air Pollution (2008) (1)
Cardiac donor heart dysfunction: Evidence for catecholamine-mediated myocardial injury (1990) (1)
OKT3 therapy as a cause of high panel-reactive antibodies in serum using standard microcytotoxicity techniques. (1988) (1)
Sensitization to OKT3: Increased frequency with prolonged administration (1990) (1)
Multiple coronary thromboses in previously normal coronary arteries treated with streptokinase. (1987) (1)
The patient knows best: perceptions of family versus patient report of symptoms (2004) (1)
Impact of prophylactic immediate post-transplant genciclovir on development of transplant atherosclerosis: A randomized placebo-controlled study (1996) (1)
435: Long-term outcomes of transplantation for peripartum cardiomyopathy. A multiinstitutional analysis (2007) (1)
Abstract 2702: Changes in Filling Pressures Rather than in Daily Weights Predict Heart Failure Events with Active Heart Failure Disease Management (2007) (1)
Twelve months results of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de novo heart transplant patients showed excellent efficacy and safety (2005) (1)
102: Predictors of long-term survival in destination therapy left ventricular assist device patients (2006) (1)
Abstract 2956: Validation of the Seattle Heart Failure Model in a Heart Failure Population in a 20 Hospital System in the Intermountain West (2006) (1)
1098-81 Which white blood cell compartments predict increased cardiovascular risk? (2004) (1)
334: Causes for hospital readmission in destination therapy LVAD patients (2007) (0)
Abstract 2714: Heart Failure Device Therapy: Effect of Age and Gender on Patient Survival (2007) (0)
SAFETY, TOLERABILITY, AND EFFICACY OF CYCLOSPORINE MICROEMULSION IN HEART TRANSPLANT RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND COMPARISON WITH THE OIL-BASED FORMULATION OF CYCLOSPORINE—RESULTS AT 24 MONTHS AFTER TRANSPLANTATION1 (2001) (0)
193: Antibody-Mediated Rejection in Heart Transplantation: More Than Present-or-Absent (2008) (0)
Time-Dependent Changes in Serum B-Type Natriuretic Peptide (BNP) after Heart Transplantation: Correlation with Rejection Patterns and Allograft Function (2006) (0)
One hospital system's success to meet JCAHO mandates for heart failure education (2003) (0)
Left Ventricular Function During Two Sequential Exercise Periods Separated by One Hour Without Intervention (1986) (0)
Status Is More Predictive of Increased Hazard in Women Than Men After Angiographic Diagnosis of Coronary Artery Disease (2016) (0)
Subject Index Vol. 104, 2005 (2005) (0)
Renal dysfunction is more likely in recipients bridged to heart transplantation with inotropes than with left ventricular assist devices: an analysis of pre-transplant characteristics in the modern era (2004) (0)
186: Differential Sensitization Incidence between HeartMate I and HeartMate II Left Ventricular Assist Devices (2009) (0)
State of the art immunosuppressive regimens: routine and rescue (1992) (0)
300: Risk Factors for Neurological Events in Long-Term Mechanical Circulatory Support Patients (2008) (0)
Heart Failure Mortality Predicted by a Calculated Basic Metabolic Profile Risk Score (2006) (0)
Clinical Investigations The Cost of Medical Management in Advanced Heart Failure During the Final Two Years of Life (2008) (0)
Better Compliance by Cardiologists Than Non-Cardiologists in Documenting JCAHO Heart Failure Measures (2006) (0)
Safety and efficacy of intraoperative vs postoperative administration of okt3 in orthotopic cardiac transplantation (1990) (0)
New Pharmacologic Immunosuppressive Agents (1996) (0)
Assessment of the impact of JCAHO-required inpatient heart failure education: evaluation of 1,331 discharged patients in a multi-hospital system (2004) (0)
Does secondary prevention with statins eliminate the risk of hyperhomocysteinemia (2003) (0)
716: The Impact of 2006 United Network for Organ Sharing Thoracic Organ Allocation Policy Change: Mission Accomplished? (2009) (0)
Angiotensin converting enzyme inhibition reduces elevated C-reactive protein in patients with angiographic coronary artery disease (2003) (0)
The value of B-type natriuretic peptide in predicting allograft rejection in cardiac transplant recipients (2004) (0)
81: Impact of Cold Ischemic Time on Post-Transplant Cardiac Outcomes and Rejection (2009) (0)
1163-112 Homocysteine levels predict risk for congestive heart failure in patients with and without coronary artery disease (2004) (0)
Late survival after heart transplantation: are we getting better at long-term management? (2004) (0)
Increased incidence of surgical reexploration for postoperative bleeding due to early postoperative use of unfractionated heparin or enoxaparin (2002) (0)
Blockade WithBucindolol inHeartFailure CausedbyIschemic VersusIdiopathic Dilated Cardiomyopathy (1991) (0)
299: Outcomes of non-cardiac surgery in patients with mechanical circulatory support (2006) (0)
Cardiac transplantation--the need for prospective, randomized, controlled investigations. (1988) (0)
Which features of the metabolic syndrome predict the presence of angiographic coronary artery disease (2003) (0)
Hematocrit-associated improvement in survival after initial heart failure hospitalization: analysis of 2,385 patients in an integrated healthcare system (2004) (0)
Clinical Outcomes and Chronic Management of Device Patients (2009) (0)
2: Virtual Crossmatch Should Be Utilized in Sensitized Patients To Improve Organ Allocation (2008) (0)
100 PATIENT-YEARS OF VENTRICULAR ASSIST DEVICE SUPPORT: THE UTAH ARTIFICIAL HEART PROGRAM EXPERIENCE (2006) (0)
Predictors of Persistently Elevated Pulmonary Vascular Resistance after the Insertion of Implantable Left Ventricular Assist Devices (2006) (0)
359: Virtual crossmatch improves organ allocation in sensitized patients (2007) (0)
The intermountain risk model: predicting mortality by traditional and novel risk factors among patients with significant coronary disease (2002) (0)
The impact of a positive donor-specific crossmatch on outcome after heart transplantion (2003) (0)
The contribution of blood product transfusions to HLA allosensitization in LVAD recipients (2003) (0)
Implementation of an automated reporting system improves data collection on heart failure patients in a multi-hospital, integrated healthcare delivery system (2004) (0)
Abstract 3987: Short-Term Exposure to Fine Particulate Air Pollution is Associated with the Risk of Ischemic Coronary Events, Especially among Patients with Coronary Disease (2006) (0)
Which features of the metabolic syndrome predict clinical outcomes (death/myocardial infarction) in patients with angiographic coronary artery disease? (2003) (0)
Do statins provide clinical benefit in high-risk coronary artery disease patients with advanced left ventricular dysfunction? (2003) (0)
Daily Weights at Home Are Not Reliable for Tracking Fluid Change before Heart Failure Events (2007) (0)
Troponin-I and C-reactive protein have independent value for prediction of long-term risk after acute coronary syndromes: Utility of troponin-I is increased for women (2003) (0)
Prior HLA allosensitization predisposes patients to become and remain highly sensitized after LVAD implantation (2003) (0)
Low socioeconomic status is more predictive of increased hazard in women than men after angiographic diagnosis of coronary artery disease (2003) (0)
Obesity paradox validation-elevated body mass index portends a better prognosis in heart failure: analysis of 2,707 patients in an integrated healthcare delivery system (2004) (0)
Cardiac transplantation: 1. From CHF to surgery. (1994) (0)
Introduction: Cardiac Transplantation (1997) (0)
Low-dose prophylactic intravenous immunoglobulin does not prevent HLA allosensitization in LVAD recipients (2004) (0)
83: Incremental survival benefit with better adherence to JCAHO heart failure core performance measures: A study of 2144 patients (2006) (0)
THORATEC RIGHT VENTRICULAR ASSIST DEVICE WITH CONCURRENT HEARTMATE XVE LEFT VENTRICULAR ASSIST DEVICE: LONG-TERM OUTPATIENT MANAGEMENT (2006) (0)
296: Providing long-term care to destination therapy LVAD recipients in distant communities: Partnering with local teams (2006) (0)
Effect of Mechanical Circulatory Support on Pulmonary Hypertension Assessed by Implantable Hemodynamic Monitoring (2006) (0)
Perspectives* Consensus Statement: Palliative and Supportive Care in Advanced Heart Failure (2004) (0)
Cardiac transplantation. (1997) (0)
385: Advanced Cardiac Allograft Vasculopathy Results in a Unique Cardiac Remodeling Pattern (2009) (0)
human heart. Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing (2013) (0)
Myocarditis (2020) (0)
HorneBD IMRS supplemental tables AmJMed-2009 (2014) (0)
C4d in antibody-mediated rejection-how sensitive is it? (2005) (0)
Pathology of Cardiac Allograft Vascular (Microvascular) Rejection: Impact on Patient Outcomes (2001) (0)
Cardiac transplantation: 2. Life with a new heart. (1994) (0)
194: Adequate cyclosporine (CsA) microemulsion (Neoral®) C2-levels critical within the first 30 days to prevent rejection after cardiac transplant (2006) (0)
with Increased Surgical Re-Exploration for Bleeding Early Postoperative Use of Unfractionated Heparin or Enoxaparin is Associated (2013) (0)
Contents Vol. 104, 2005 (2005) (0)
192: The impact of a repetitive cellular or antibody-mediated rejection pattern on cardiovascular death in heart transplant recipients (2006) (0)
Can histologic parameters be used to screen biopsies for antibody mediated rejection? A retrospective study of 3179 biopsies (2005) (0)
Replication of Genome-Wide Association of the PTHLH-KLHDC5 Locus with Peripartum Cardiomyopathy (2010) (0)
SANGCYA IS BIOEQUIVALENT TO NEORAL IN STABLE CARDIAC ALLOGRAFT PATIENTS (1999) (0)
308: Treatment of hypertension in destination LVAD recipients: A single center analysis (2006) (0)

This paper list is powered by the following services:

Other Resources About Dale G. Renlund

en.wikipedia.org

What Schools Are Affiliated With Dale G. Renlund?

Dale G. Renlund is affiliated with the following schools:

Why Is Dale G. Renlund Influential?

Dale G. Renlund's Published Works

Published Works

Other Resources About Dale G. Renlund

What Schools Are Affiliated With Dale G. Renlund?

Image Attributions